Pauline van Eeden

Phone: +61 8 9224 0356
Email: pvaneeden@meddent.uwa.edu.au

Pauline van Eeden is currently near completion of her PhD thesis which studies the role of Vascular Endothelial Growth Factor (VEGF) in blood vessel development in a transgenic model of retinal neovascularisation. She was awarded her Honours Degree from the University of RMIT in 1994 for her work investigating apolipoprotein allele frequencies in a variety of ethnic populations as well as in Alzheimer's patients.

Her current projects include:

Australian Ant Venom Allergy Study (AAVAS) - this study includes the national mapping of major ant species responsible for anaphylaxis, identification of specific allergens, the compilation of reference venom and allergic sera, development of accurate diagnostic tests and production of high quality venom extracts for human immunotherapy (VIT).

Jack Jumper Allergy Program - analysis of samples from a clinical trial of Jack Jumper Ant Venom Immunotherapy (assessing changes in venom-specific immunoglobulins and cytokine production during the time course of immunotherapy and correlation with clinical endpoints).

Australian Snakebite Project (ASP) and the Redback Antivenom Evaluation (RAVE) - these projects investigate the nature of anaphylaxis to Australian and Sri Lankan snake and spider venom and responses to the specific antivenoms used to treat these reactions.

Qualifications

1994	BAppSc (Hons) - Medical Laboratory Science, RMIT University, Australia

Research Interests

• Immune mechanisms of allergy and immunotherapy.
• Genetics of anaphylaxis.
• Immune mechanisms of critical illness.

Top Publications

1. van Eeden PE, Tee L, Shen W-Y, Lukehurst S, Lai C-M, Rakoczy PE, Beazley LD, Dunlop SA. 2006. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularisation. Investigative Ophthalmology & Visual Science 47(10):4638-45. [NCBI PubMed Entry]
2. van Eeden PE, Tee L, Shen W-Y, Lukehurst S, Lai C-M, Rakoczy PE, Beazley LD, Dunlop SA. 2006. Characterisation of a model for retinal neovascularisation. Advances in Experimental Medicine and Biology 572:163-8. [NCBI PubMed Entry]
3. Beilharz MW, Sammels LM, Paun A, Shaw K, van Eeden PE, Watson MW, Ashdown ML. 2004. Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression. Journal of Immunology 172(8):4917-25. [NCBI PubMed Entry]
4. Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeden PE, Allen TJ, Kelly DJ, Cooper ME. 2000. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circulation Research 86(2):158-65. [NCBI PubMed Entry]
5. Ramsay RG, Morrice N, van Eeden PE, Kanagasundaram V, Nomura T, Deblaquiere J, Ishii S, Wettenhall R. 1995. Regulation of c-myb through protein phosphorylation and leucine zipper interactions. Oncogene 11(10):2113-20. [NCBI PubMed Entry]
6. Whitehead RH, van Eeden PE, Noble MD, Ataliotis P, Jat PS. 1993. The establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proceedings of the National Academy of Sciences of the USA 90(2):587-91. [NCBI PubMed Entry]
7. Whitehead RH, van Eeden PE. 1991. A method for the prolonged culture of colonic epithelial cells. Journal of Tissue Culture Methods 13:103-106.
8. Whitehead RH, van Eeden PE, Lukeis RE. 1991. A Cell line (LIM 2463) derived from a Tubulovillous adenoma of the rectum. International Journal of Cancer 48(5):693-6. [NCBI PubMed Entry]